Drug Trial Radar · NCT03976063
Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
857
Actual
Start
Oct 7, 2019
Primary completion
Nov 2026
Study completion Nov 2031
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France; Ministry of Health, France; Groupe de Recherche en Obstétrique et Gynécologie; URC-CIC Paris Descartes Necker Cochin
- First posted
- Jun 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.
Conditions
- Preterm Premature Rupture of Membrane
Interventions
NifedipineDrug
Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
Placebo of NifedipineDrug
Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
Primary outcomes
What the sponsor says the trial is designed to measure.
- Perinatal morti-morbidityTime frame: Up to discharge from hospital, with a maximum of 24 weeks after birth.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Trousseau University Hospital
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.